Michael (Mike) Wyzga MBA, B.S Fin.


Michael (Mike) Wyzga is the Founder of MSW Consulting, Inc., a strategic consulting group focused on pharmaceutical and biotech industries. Previously, he served as President, CEO, and a member of the Board of Directors of Radius Health, Inc., a specialty biopharmaceutical company dedicated to bone health and expanding access for patients. Prior to that, Mike held numerous senior management positions at Genzyme Corporation, including as Executive Vice President and Chief Financial Officer, and played roles in the successful development and commercialization of several vital therapies, including Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, Renagel for use in the treatment of hyperphosphatemia, and Campath for chronic lymphocytic leukemia.

Currently, Mike serves on four public company Boards, including as Chairman of the Board of X4 Pharmaceuticals, GenSight Biologics, and Mereo BioPharma Group plc, as well as Chair of the Audit Committee at Invivyd, Inc. He received an MBA from Providence College and a B.S. from Suffolk University.